Minimizing Acute Toxicity and Late Effects in the Treatment of Hodgkin Lymphoma in Patients with Sickle Cell Disease.

Advances in treatment have reduced mortality from Hodgkin Lymphoma (HL) and made it so greater attention can be focused on minimizing late effects. A variety of risk-adapted treatment regimens exist that prioritize disease presentation, but not patient-specific comorbidities. Herein we describe a patient with sickle cell disease diagnosed with HL and the considerations made in treatment planning to minimize therapy-related acute toxicity and late effects that overlap with the patient's preexisting sickle cell disease complications.